Nanjing Gaoke Co

Nanjing Gaoke Co EBITDA per Share

The EBITDA per Share of Nanjing Gaoke Co (600064.SS) as of Oct 28, 2026 is 0.20 CNY. In the previous year, EBITDA per Share was -0.33 CNY — a change of -161.68% (higher).

EBITDA per Share

0.20CNY

YoY

-161.68%

Last updated:

EBITDA per Share of Nanjing Gaoke Co is 2025 0.20 CNY. EBITDA per Share of Nanjing Gaoke Co was 2024 -0.33 CNY. It decreases by -161.68% higher compared to the previous year.

The Nanjing Gaoke Co EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
1.21 CNY
Jan 1, 2019
1.20 CNY
Jan 1, 2020
1.39 CNY
Jan 1, 2021
0.37 CNY
Jan 1, 2022
0.38 CNY
Jan 1, 2023
-0.13 CNY
Jan 1, 2024
-0.33 CNY
Jan 1, 2025
0.20 CNY
The Nanjing Gaoke Co EBITDA per Share history
YEAREBITDA per ShareYoY
0.20CNY-161.68%
-0.33CNY+148.29%
-0.13CNY-134.66%
0.38CNY+2.67%
0.37CNY-73.34%
1.39CNY+15.88%
1.20CNY-1.49%
1.21CNY+17.27%
1.04CNY+2.61%
1.01CNY+15.56%
0.87CNY+42.34%
0.61CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nanjing Gaoke Co Stock analysis

What does Nanjing Gaoke Co do? Nanjing Gaoke Co., Ltd. generates revenue through its property and municipal business, pharmaceutical operations, and equity investment activities. The company develops residential and commercial properties, manages real estate assets, and provides municipal services in Nanjing, Jiangsu province. Its pharmaceutical business focuses on research, manufacturing, and selling drugs, while equity investments contribute to its income stream. The primary customers for real estate are residents and businesses seeking residential or commercial spaces, and pharmaceutical buyers include healthcare providers and patients in the local market. The company's property and municipal business serves local communities and businesses in Nanjing, Jiangsu, with residential development and property management as key revenue drivers. Pharmaceutical sales target healthcare institutions and end-users within Jiangsu province, leveraging the firm's R&D capabilities. Equity investment activities support diversified income generation without specifying external partners or markets. Nanjing Gaoke's real estate segment includes residential and commercial projects, while its pharmaceutical division handles drug production and distribution. The firm's municipal services integrate with property management to enhance community offerings. Equity investments provide additional financial returns, though specific investment targets are not detailed in the description. Nanjing Gaoke Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nanjing Gaoke Co stock

EBITDA per Share of Nanjing Gaoke Co is 0.20 CNY in 2025.

EBITDA per Share of Nanjing Gaoke Co changed from -0.33 CNY to 0.20 CNY, representing a -161.68% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Nanjing Gaoke Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Nanjing Gaoke Co

All Key Metrics — Nanjing Gaoke Co